Abstract
Somatostatin receptor-targeting peptides are widely being used for imaging and therapy of neuroendocrine tumors. Peptide receptor radionuclide therapy (PRRT) with e.g. 177Lu labeled somatostatin analogues in neuroendocrine tumor patients has resulted in symptomatic improvement, prolonged survival and enhanced quality of life. Yet, much profit can be gained from improving the receptor-targeting strategies available and developing new strategies, e.g. targeting other tumor-specific receptors, such as gastrin-releasing peptide (GRP) receptors and gastrin/cholecystokinin (CCK) receptors, and combining PRRT with other treatment strategies like chemotherapy or co-treatment with radiosensitizers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
